Premium
Quetiapine treatment in early psychosis: 1 year outcomes
Author(s) -
Kopala L.,
Woodley H.,
Campbell L. A.,
Gallant J.,
Rui Q.,
Milliken H.,
Whitehorn D.
Publication year - 2002
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1034/j.1600-0447.106.s413.1_12.x
Subject(s) - quetiapine , psychosis , antipsychotic , adverse effect , medicine , schizophrenia (object oriented programming) , dosing , psychiatry , quetiapine fumarate , antipsychotic agent , global assessment of functioning , clinical trial , atypical antipsychotic , psychology
Objective To determine clinical response, dosing and adverse events associated with quetiapine treatment in early psychosis. Method 40 Patients (33 men; 7 women; mean age 23.75) with schizophrenia spectrum disorders and less than 6 months previous exposure to antipsychotic treatment, entered an open label, 2 years, flexible dose trial and were assessed with PANSS, CGI, GAF, SOFAS, ESRS, BMI and ocular exams at baseline and 6 month intervals thereafter. Results Among 30 patients who enrolled >1 years ago, 19 (63%) completed 1‐year assessment. Dropouts were due to insufficient clinical response (13%), nonadherence (13%) and personal choice (10%). At 1 year, significant improvement was observed on the PANSS, CGI, GAF and SOFAS. Mean dose was 559 (±207) mg/day. No drug induced EPS was noted and EPS present at baseline was reduced. Mean change in BMI was 17% (±22). No ocular changes were observed. Conclusions Quetiapine was well tolerated. Clinical response was similar to that achieved with other second generation antipsychotic agents in the same early psychosis programme.